BridgeBio Oncology Therapeutics (BBOT) Income from Continuing Operations (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 62087000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 193.59% year-over-year to 62087000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 232334849.0 (down 130.54% YoY) and the FY2025 annual result came in at 233001000.0, down 98.14% from the prior year.
• Income from Continuing Operations grew to 62087000.0 in Q1 2026 per BBOT's latest filing, from 86179000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 2289936.0 in Q2 2024 and troughed at 86179000.0 in Q4 2025.
• A 3-year average of 36886148.22 and a median of 21147732.0 in 2025 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 32.97% in 2025, down 1955.37% in 2025.
• Over 3 years, Income from Continuing Operations stood at 64813113.0 in 2024, then plunged by 32.97% to 86179000.0 in 2025, then grew by 27.96% to 62087000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 62087000.0, 86179000.0, and 85022000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.